From this panel, we selected two pairs of CRC-SCs: #1SENS/#1RES and #19SENS/#19RES, and used them to identify novel actionable targets improving the sensitivity and/or reverting the resistance to CHK1 inhibitors. This evidence concerns the gene CHEK1 and colorectal carcinoma.